Medical Progress: Recent Advances in Neuroblastoma.

被引：1470
作者：
Maris, John M. [1 ,2 ]
机构：
[1] Univ Penn, Childrens Hosp Philadelphia, Div Oncol, Ctr Childhood Canc Res,Sch Med, Philadelphia, PA 19104 USA
[2] Abramson Family Canc Res Inst, Philadelphia, PA USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2010年 / 362卷 / 23期
关键词：
HIGH-RISK NEUROBLASTOMA; CHILDRENS ONCOLOGY GROUP; AUTOLOGOUS BONE-MARROW; BLASTOMA CELLS-INVITRO; HUMAN NEURO-BLASTOMA; EVENT-FREE SURVIVAL; PHASE-II; REFRACTORY NEUROBLASTOMA; SPONTANEOUS REGRESSION; MONOCLONAL-ANTIBODY;
D O I：
10.1056/NEJMra0804577
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2202 / 2211
页数：10
相关论文
共 69 条
  • [1] Asgharzadeh S, 2006, JNCI-J NATL CANCER I, V98, P1193, DOI 10.1093/jnci/djj330
  • [2] BARKER E, 1993, CANCER RES, V53, P362
  • [3] Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force
    Beiske, K.
    Burchill, S. A.
    Cheung, I. Y.
    Hiyama, E.
    Seeger, R. C.
    Cohn, S. L.
    Pearson, A. D. J.
    Matthay, K. K.
    [J]. BRITISH JOURNAL OF CANCER, 2009, 100 (10) : 1627 - 1637
  • [4] Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial
    Berthold, F
    Boos, J
    Burdach, S
    Erttmann, R
    Henze, G
    Hermann, J
    Klingebiel, T
    Kremens, B
    Schilling, FH
    Schrappe, M
    Simon, T
    Hero, B
    [J]. LANCET ONCOLOGY, 2005, 6 (09) : 649 - 658
  • [5] An efficient targeted radiotherapy/gene therapy strategy utilising human tetomerase promoters and radioastatine and harnessing radiation-mediated bystander effects
    Boyd, M
    Mairs, RJ
    Keith, WN
    Ross, SC
    Welsh, P
    Akabani, G
    Owens, J
    Vaidyanathan, G
    Carruthers, R
    Dorrens, J
    Zalutsky, MR
    [J]. JOURNAL OF GENE MEDICINE, 2004, 6 (08) : 937 - 947
  • [6] AMPLIFICATION OF N-MYC IN UNTREATED HUMAN NEUROBLASTOMAS CORRELATES WITH ADVANCED DISEASE STAGE
    BRODEUR, GM
    SEEGER, RC
    SCHWAB, M
    VARMUS, HE
    BISHOP, JM
    [J]. SCIENCE, 1984, 224 (4653) : 1121 - 1124
  • [7] REVISIONS OF THE INTERNATIONAL CRITERIA FOR NEUROBLASTOMA DIAGNOSIS, STAGING, AND RESPONSE TO TREATMENT
    BRODEUR, GM
    PRITCHARD, J
    BERTHOLD, F
    CARLSEN, NLT
    CASTEL, V
    CASTLEBERRY, RP
    DEBERNARDI, B
    EVANS, AE
    FAVROT, M
    HEDBORG, F
    KANEKO, M
    KEMSHEAD, J
    LAMPERT, F
    LEE, REJ
    LOOK, AT
    PEARSON, ADJ
    PHILIP, T
    ROALD, B
    SAWADA, T
    SEEGER, RC
    TSUCHIDA, Y
    VOUTE, PA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (08) : 1466 - 1477
  • [8] Common variations in BARD1 influence susceptibility to high-risk neuroblastoma
    Capasso, Mario
    Devoto, Marcella
    Hou, Cuiping
    Asgharzadeh, Shahab
    Glessner, Joseph T.
    Attiyeh, Edward F.
    Mosse, Yael P.
    Kim, Cecilia
    Diskin, Sharon J.
    Cole, Kristina A.
    Bosse, Kristopher
    Diamond, Maura
    Laudenslager, Marci
    Winter, Cynthia
    Bradfield, Jonathan P.
    Scott, Richard H.
    Jagannathan, Jayanti
    Garris, Maria
    McConville, Carmel
    London, Wendy B.
    Seeger, Robert C.
    Grant, Struan F. A.
    Li, Hongzhe
    Rahman, Nazneen
    Rappaport, Eric
    Hakonarson, Hakon
    Maris, John M.
    [J]. NATURE GENETICS, 2009, 41 (06) : 718 - 723
  • [9] HOW FREQUENT IS SPONTANEOUS REMISSION OF NEUROBLASTOMAS - IMPLICATIONS FOR SCREENING
    CARLSEN, NLT
    [J]. BRITISH JOURNAL OF CANCER, 1990, 61 (03) : 441 - 446
  • [10] Surgical risk factors in primary surgery for localized neuroblastoma:: The LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group
    Cecchetto, G
    Mosseri, V
    De Bernardi, B
    Helardot, P
    Monclair, T
    Costa, E
    Horcher, E
    Neuenschwander, S
    Tomà, P
    Rizzo, A
    Michon, J
    Holmes, K
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (33) : 8483 - 8489
1234567